Taiwan Liposome Company, Ltd. [•] American Depositary Shares (par value NT$10 per share) Underwriting AgreementUnderwriting Agreement • April 16th, 2018 • Taiwan Liposome Company, Ltd. • Pharmaceutical preparations • New York
Taiwan Liposome Company, Ltd., a Taiwanese stock corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [•] American Depositary Shares (“ADSs”), representing two shares of common stock (the “Common Stock”), nominal value NT$10 per share (the “Firm Securities”) pursuant to this underwriting agreement (the “Agreement”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional [•] ADSs representing [•] shares of Common Stock pursuant to such option, which are collectively called the “Option Securities.” The Firm Securities and, if and to the extent such option is exercised, the Option Securities, are collectively called the “Offered Securities.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Securities. To the extent
ContractCommercialization Agreement • April 16th, 2018 • Taiwan Liposome Company, Ltd. • Pharmaceutical preparations
*** = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
ContractShareholders Agreement • April 16th, 2018 • Taiwan Liposome Company, Ltd. • Pharmaceutical preparations
*** = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
